peptideone
← All peptides

Adipotide

Status unknown

Also known as: 859216-15-2, HKPao, orb1981129, EX-A6186, DA-74204, T76315

Adipotide (859216-15-2, HKPao, orb1981129) is classified under other / experimental.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Adipotide is referred to in these sources as a proapoptotic peptide bioconjugate targeting adipose vascular/endothelial components in a nanoparticle-delivery context. In one comparative study, Adipotide (a bioconjugate composed of the targeting peptide and the proapoptotic component KLA) was compared with a nanoparticle-targeted therapeutic approach in diet-induced obesity (DIO) mouse models, with reported differences in body weight and related metabolic measures.

Mechanism (as reported)

A study reported that nanoparticle-targeted delivery involving a prohibitin-targeted nanoparticle (PTNP) encapsulated with a proapoptotic peptide component (KLA; described as (D)(KLAKLAK)2) aimed to target adipose vascular markers and was associated with cytoplasmic delivery into adipose endothelial cells via escape from endosomes/lysosomes. In the same study, Adipotide was described as a bioconjugate composed of the same targeting peptide and the proapoptotic component used in the PTNP approach (PMID: 23871959).

Key findings (each cites a source)

  • A comparative preclinical study reported that in DIO mice, a nanoparticle-targeted proapoptotic peptide approach (KLA-PTNP) led to a reduction in body weight and decreased serum leptin levels, whereas a bioconjugate composed of the same targeting peptide and KLA (Adipotide) was not associated with these reductions in the same way in that study’s comparison. [PMID 23871959]
  • The same comparative study reported anti-obesity effects on dysfunctional adipose cells (including adipocytes and macrophages) and reduced ectopic fat deposits in liver and muscle, alongside elevated serum adiponectin, with no detectable hepatotoxicity in the reported context. [PMID 23871959]
  • The comparative study reported that drug delivery via PTNP accumulated in obese fat via the enhanced permeability and retention (EPR) effect and was enhanced by multivalent active targeting, with cytoplasmic delivery into adipose endothelial cells described as occurring via escape from endosomes/lysosomes. [PMID 23871959]
  • A separate preclinical study reported that a proapoptotic peptide designed to induce apoptosis in white adipose tissue endothelium (HF-PP) improved glucose tolerance in obese mice in a weight- and food intake-independent manner, with decreases in serum insulin and triglycerides relative to a vehicle control in that study. [PMID 22733798]
  • The same preclinical study reported microarray changes in adipose tissue pathways related to mitochondrial dysfunction, oxidative phosphorylation, and branched-chain amino acid degradation by HFD exposure and reversal by proapoptotic peptide administration. [PMID 22733798]

Independent test grades

No independent third-party test data is available for Adipotide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (5)

Consolidated from PubMed — each links to the original record.

FAQ

What is Adipotide?
Adipotide (859216-15-2, HKPao, orb1981129) is classified under other / experimental. Research goals associated with it include metabolic & weight.
Is Adipotide FDA-approved?
The regulatory status of Adipotide is not established in our sources.
What does the research on Adipotide say?
peptideone aggregates 5 references from PubMed for Adipotide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.